-
Description
-
Table of Contents
-
Table of Figures
PDF Download
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
The global Hepatitis Drugs market size is expected to reach US$ 315010 million by 2029, growing at a CAGR of 23.8% from 2023 to 2029. The market is mainly driven by the significant applications of Hepatitis Drugs in various end use industries. The expanding demands from the Hepatitis A, Hepatitis B, Hepatitis C and Hepatitis D, are propelling Hepatitis Drugs market. VEMLIDY, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the EPCLUSA segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hepatitis Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hepatitis Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hepatitis Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hepatitis Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hepatitis Drugs covered in this report include F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie and Achillion Pharmaceuticals, etc.
The global Hepatitis Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis
Vertex Pharmaceuticals
Abbvie
Achillion Pharmaceuticals
Bristol-Myers Squibb
Global Hepatitis Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hepatitis Drugs market, Segment by Type:
VEMLIDY
EPCLUSA
SOVALDI
INCIVEK
OLYSIO
VICTRELIS
VIREAD
HEPSERA
BARACLUDE
TYZEKA
Global Hepatitis Drugs market, by Application
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Hepatitis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Hepatitis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion. 
1 Hepatitis Drugs Market Overview
1.1 Hepatitis Drugs Product Overview
1.2 Hepatitis Drugs Market Segment by Type
1.2.1 VEMLIDY
1.2.2 EPCLUSA
1.2.3 SOVALDI
1.2.4 INCIVEK
1.2.5 OLYSIO
1.2.6 VICTRELIS
1.2.7 VIREAD
1.2.8 HEPSERA
1.2.9 BARACLUDE
1.2.10 TYZEKA
1.3 Global Hepatitis Drugs Market Size by Type
1.3.1 Global Hepatitis Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Hepatitis Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Hepatitis Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Hepatitis Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Hepatitis Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Hepatitis Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Hepatitis Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Hepatitis Drugs Sales Breakdown by Type (2018-2023)
2 Global Hepatitis Drugs Market Competition by Company
2.1 Global Top Players by Hepatitis Drugs Sales (2018-2023)
2.2 Global Top Players by Hepatitis Drugs Revenue (2018-2023)
2.3 Global Top Players by Hepatitis Drugs Price (2018-2023)
2.4 Global Top Manufacturers Hepatitis Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Hepatitis Drugs Market Competitive Situation and Trends
2.5.1 Hepatitis Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Hepatitis Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Hepatitis Drugs Market
2.8 Key Manufacturers Hepatitis Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Hepatitis Drugs Status and Outlook by Region
3.1 Global Hepatitis Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Hepatitis Drugs Historic Market Size by Region
3.2.1 Global Hepatitis Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Hepatitis Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Hepatitis Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Hepatitis Drugs Forecasted Market Size by Region
3.3.1 Global Hepatitis Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Hepatitis Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Hepatitis Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Hepatitis Drugs by Application
4.1 Hepatitis Drugs Market Segment by Application
4.1.1 Hepatitis A
4.1.2 Hepatitis B
4.1.3 Hepatitis C
4.1.4 Hepatitis D
4.1.5 Hepatitis E
4.2 Global Hepatitis Drugs Market Size by Application
4.2.1 Global Hepatitis Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Hepatitis Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Hepatitis Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Hepatitis Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Hepatitis Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Hepatitis Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Hepatitis Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Hepatitis Drugs Sales Breakdown by Application (2018-2023)
5 North America Hepatitis Drugs by Country
5.1 North America Hepatitis Drugs Historic Market Size by Country
5.1.1 North America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Hepatitis Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Hepatitis Drugs Sales in Value by Country (2018-2023)
5.2 North America Hepatitis Drugs Forecasted Market Size by Country
5.2.1 North America Hepatitis Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Hepatitis Drugs Sales in Value by Country (2024-2029)
6 Europe Hepatitis Drugs by Country
6.1 Europe Hepatitis Drugs Historic Market Size by Country
6.1.1 Europe Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Hepatitis Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Hepatitis Drugs Sales in Value by Country (2018-2023)
6.2 Europe Hepatitis Drugs Forecasted Market Size by Country
6.2.1 Europe Hepatitis Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Hepatitis Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Hepatitis Drugs by Region
7.1 Asia-Pacific Hepatitis Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Hepatitis Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Hepatitis Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Hepatitis Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Hepatitis Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Hepatitis Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Hepatitis Drugs Sales in Value by Region (2024-2029)
8 Latin America Hepatitis Drugs by Country
8.1 Latin America Hepatitis Drugs Historic Market Size by Country
8.1.1 Latin America Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Hepatitis Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Hepatitis Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Hepatitis Drugs Forecasted Market Size by Country
8.2.1 Latin America Hepatitis Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Hepatitis Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Hepatitis Drugs by Country
9.1 Middle East and Africa Hepatitis Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Hepatitis Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Hepatitis Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Hepatitis Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Hepatitis Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Hepatitis Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Hepatitis Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 F. Hoffmann-La Roche
10.1.1 F. Hoffmann-La Roche Company Information
10.1.2 F. Hoffmann-La Roche Introduction and Business Overview
10.1.3 F. Hoffmann-La Roche Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 F. Hoffmann-La Roche Hepatitis Drugs Products Offered
10.1.5 F. Hoffmann-La Roche Recent Development
10.2 Gilead Sciences
10.2.1 Gilead Sciences Company Information
10.2.2 Gilead Sciences Introduction and Business Overview
10.2.3 Gilead Sciences Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Gilead Sciences Hepatitis Drugs Products Offered
10.2.5 Gilead Sciences Recent Development
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Company Information
10.3.2 GlaxoSmithKline Introduction and Business Overview
10.3.3 GlaxoSmithKline Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 GlaxoSmithKline Hepatitis Drugs Products Offered
10.3.5 GlaxoSmithKline Recent Development
10.4 Johnson & Johnson
10.4.1 Johnson & Johnson Company Information
10.4.2 Johnson & Johnson Introduction and Business Overview
10.4.3 Johnson & Johnson Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Johnson & Johnson Hepatitis Drugs Products Offered
10.4.5 Johnson & Johnson Recent Development
10.5 Merck
10.5.1 Merck Company Information
10.5.2 Merck Introduction and Business Overview
10.5.3 Merck Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merck Hepatitis Drugs Products Offered
10.5.5 Merck Recent Development
10.6 Novartis
10.6.1 Novartis Company Information
10.6.2 Novartis Introduction and Business Overview
10.6.3 Novartis Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Novartis Hepatitis Drugs Products Offered
10.6.5 Novartis Recent Development
10.7 Vertex Pharmaceuticals
10.7.1 Vertex Pharmaceuticals Company Information
10.7.2 Vertex Pharmaceuticals Introduction and Business Overview
10.7.3 Vertex Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Vertex Pharmaceuticals Hepatitis Drugs Products Offered
10.7.5 Vertex Pharmaceuticals Recent Development
10.8 Abbvie
10.8.1 Abbvie Company Information
10.8.2 Abbvie Introduction and Business Overview
10.8.3 Abbvie Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Abbvie Hepatitis Drugs Products Offered
10.8.5 Abbvie Recent Development
10.9 Achillion Pharmaceuticals
10.9.1 Achillion Pharmaceuticals Company Information
10.9.2 Achillion Pharmaceuticals Introduction and Business Overview
10.9.3 Achillion Pharmaceuticals Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Achillion Pharmaceuticals Hepatitis Drugs Products Offered
10.9.5 Achillion Pharmaceuticals Recent Development
10.10 Bristol-Myers Squibb
10.10.1 Bristol-Myers Squibb Company Information
10.10.2 Bristol-Myers Squibb Introduction and Business Overview
10.10.3 Bristol-Myers Squibb Hepatitis Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Bristol-Myers Squibb Hepatitis Drugs Products Offered
10.10.5 Bristol-Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Hepatitis Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Hepatitis Drugs Industrial Chain Analysis
11.4 Hepatitis Drugs Market Dynamics
11.4.1 Hepatitis Drugs Industry Trends
11.4.2 Hepatitis Drugs Market Drivers
11.4.3 Hepatitis Drugs Market Challenges
11.4.4 Hepatitis Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Hepatitis Drugs Distributors
12.3 Hepatitis Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
List of Tables
Table 1. Major Company of VEMLIDY
Table 2. Major Company of EPCLUSA
Table 3. Major Company of SOVALDI
Table 4. Major Company of INCIVEK
Table 5. Major Company of OLYSIO
Table 6. Major Company of VICTRELIS
Table 7. Major Company of VIREAD
Table 8. Major Company of HEPSERA
Table 9. Major Company of BARACLUDE
Table 10. Major Company of TYZEKA
Table 11. Global Hepatitis Drugs Sales by Type 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Hepatitis Drugs Sales by Type (2018-2023) & (K Units)
Table 13. Global Hepatitis Drugs Sales Market Share in Volume by Type (2018-2023)
Table 14. Global Hepatitis Drugs Sales by Type (2018-2023) & (US& Million)
Table 15. Global Hepatitis Drugs Market Share in Value by Type (2018-2023)
Table 16. Global Hepatitis Drugs Price by Type (2018-2023) & (USD/Unit)
Table 17. Global Hepatitis Drugs Sales by Type (2024-2029) & (K Units)
Table 18. Global Hepatitis Drugs Sales Market Share in Volume by Type (2024-2029)
Table 19. Global Hepatitis Drugs Sales by Type (2024-2029) & (US$ Million)
Table 20. Global Hepatitis Drugs Sales Market Share in Value by Type (2024-2029)
Table 21. Global Hepatitis Drugs Price by Type (2024-2029) & (USD/Unit)
Table 22. North America Hepatitis Drugs Sales by Type (2018-2023) & (K Units)
Table 23. North America Hepatitis Drugs Sales by Type (2018-2023) & (US$ Million)
Table 24. Europe Hepatitis Drugs Sales (K Units) by Type (2018-2023)
Table 25. Europe Hepatitis Drugs Sales by Type (2018-2023) & (US$ Million)
Table 26. Asia-Pacific Hepatitis Drugs Sales (K Units) by Type (2018-2023)
Table 27. Asia-Pacific Hepatitis Drugs Sales by Type (2018-2023) & (US$ Million)
Table 28. Latin America Hepatitis Drugs Sales (K Units) by Type (2018-2023)
Table 29. Latin America Hepatitis Drugs Sales by Type (2018-2023) & (US$ Million)
Table 30. Middle East and Africa Hepatitis Drugs Sales (K Units) by Type (2018-2023)
Table 31. Middle East and Africa Hepatitis Drugs Sales by Type (2018-2023) & (US$ Million)
Table 32. Global Hepatitis Drugs Sales by Company (2018-2023) & (K Units)
Table 33. Global Hepatitis Drugs Sales Share by Company (2018-2023)
Table 34. Global Hepatitis Drugs Revenue by Company (2018-2023) & (US$ Million)
Table 35. Global Hepatitis Drugs Revenue Share by Company (2018-2023)
Table 36. Global Market Hepatitis Drugs Price by Company (2018-2023) & (USD/Unit)
Table 37. Global Hepatitis Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 38. Global Hepatitis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 39. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hepatitis Drugs as of 2022)
Table 40. Date of Key Manufacturers Enter into Hepatitis Drugs Market
Table 41. Key Manufacturers Hepatitis Drugs Product Type
Table 42. Mergers & Acquisitions, Expansion Plans
Table 43. Global Hepatitis Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2029
Table 44. Global Hepatitis Drugs Sales by Region (2018-2023) & (K Units)
Table 45. Global Hepatitis Drugs Sales Market Share in Volume by Region (2018-2023)
Table 46. Global Hepatitis Drugs Sales by Region (2018-2023) & (US$ Million)
Table 47. Global Hepatitis Drugs Sales Market Share in Value by Region (2018-2023)
Table 48. Global Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 49. Global Hepatitis Drugs Sales by Region (2024-2029) & (K Units)
Table 50. Global Hepatitis Drugs Sales Market Share in Volume by Region (2024-2029)
Table 51. Global Hepatitis Drugs Sales by Region (2024-2029) & (US$ Million)
Table 52. Global Hepatitis Drugs Sales Market Share in Value by Region (2024-2029)
Table 53. Global Hepatitis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2029)
Table 54. Global Hepatitis Drugs Sales by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 55. Global Hepatitis Drugs Sales by Application (2018-2023) & (K Units)
Table 56. Global Hepatitis Drugs Sales Market Share in Volume by Application (2018-2023)
Table 57. Global Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 58. Global Hepatitis Drugs Sales Market Share in Value by Application (2018-2023)
Table 59. Global Hepatitis Drugs Price by Application (2018-2023) & (USD/Unit)
Table 60. Global Hepatitis Drugs Sales by Application (2024-2029) & (K Units)
Table 61. Global Hepatitis Drugs Sales Market Share in Volume by Application (2024-2029)
Table 62. Global Hepatitis Drugs Sales by Application (2024-2029) & (US$ Million)
Table 63. Global Hepatitis Drugs Sales Market Share in Value by Application (2024-2029)
Table 64. Global Hepatitis Drugs Price by Application (2024-2029) & (USD/Unit)
Table 65. North America Hepatitis Drugs Sales by Application (2018-2023) (K Units)
Table 66. North America Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 67. Europe Hepatitis Drugs Sales by Application (2018-2023) (K Units)
Table 68. Europe Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 69. Asia-Pacific Hepatitis Drugs Sales by Application (2018-2023) (K Units)
Table 70. Asia-Pacific Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 71. Latin America Hepatitis Drugs Sales by Application (2018-2023) (K Units)
Table 72. Latin America Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 73. Middle East and Africa Hepatitis Drugs Sales by Application (2018-2023) (K Units)
Table 74. Middle East and Africa Hepatitis Drugs Sales by Application (2018-2023) & (US$ Million)
Table 75. North America Hepatitis Drugs Sales by Country (2018-2023) & (K Units)
Table 76. North America Hepatitis Drugs Sales Market Share in Volume by Country (2018-2023)
Table 77. North America Hepatitis Drugs Sales by Country (2018-2023) & (US$ Million)
Table 78. North America Hepatitis Drugs Sales Market Share in Value by Country (2018-2023)
Table 79. North America Hepatitis Drugs Sales by Country (2024-2029) & (K Units)
Table 80. North America Hepatitis Drugs Sales Market Share in Volume by Country (2024-2029)
Table 81. North America Hepatitis Drugs Sales by Country (2024-2029) & (US$ Million)
Table 82. North America Hepatitis Drugs Sales Market Share in Value by Country (2024-2029)
Table 83. Europe Hepatitis Drugs Sales by Country (2018-2023) & (K Units)
Table 84. Europe Hepatitis Drugs Sales Market Share in Volume by Country (2018-2023)
Table 85. Europe Hepatitis Drugs Sales by Country (2018-2023) & (US$ Million)
Table 86. Europe Hepatitis Drugs Sales Market Share in Value by Country (2018-2023)
Table 87. Europe Hepatitis Drugs Sales by Country (2024-2029) & (K Units)
Table 88. Europe Hepatitis Drugs Sales Market Share in Volume by Country (2024-2029)
Table 89. Europe Hepatitis Drugs Sales by Country (2024-2029) & (US$ Million)
Table 90. Europe Hepatitis Drugs Sales Market Share in Value by Country (2024-2029)
Table 91. Asia-Pacific Hepatitis Drugs Sales by Region (2018-2023) & (K Units)
Table 92. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Region (2018-2023)
Table 93. Asia-Pacific Hepatitis Drugs Sales by Region (2018-2023) & (US$ Million)
Table 94. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Region (2018-2023)
Table 95. Asia-Pacific Hepatitis Drugs Sales by Region (2024-2029) & (K Units)
Table 96. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Region (2024-2029)
Table 97. Asia-Pacific Hepatitis Drugs Sales by Region (2024-2029) & (US$ Million)
Table 98. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Region (2024-2029)
Table 99. Latin America Hepatitis Drugs Sales by Country (2018-2023) & (K Units)
Table 100. Latin America Hepatitis Drugs Sales Market Share in Volume by Country (2018-2023)
Table 101. Latin America Hepatitis Drugs Sales by Country (2018-2023) & (US$ Million)
Table 102. Latin America Hepatitis Drugs Sales Market Share in Value by Country (2018-2023)
Table 103. Latin America Hepatitis Drugs Sales by Country (2024-2029) & (K Units)
Table 104. Latin America Hepatitis Drugs Sales Market Share in Volume by Country (2024-2029)
Table 105. Latin America Hepatitis Drugs Sales by Country (2024-2029) & (US$ Million)
Table 106. Latin America Hepatitis Drugs Sales Market Share in Value by Country (2024-2029)
Table 107. Middle East and Africa Hepatitis Drugs Sales by Country (2018-2023) & (K Units)
Table 108. Middle East and Africa Hepatitis Drugs Sales Market Share in Volume by Country (2018-2023)
Table 109. Middle East and Africa Hepatitis Drugs Sales by Country (2018-2023) & (US$ Million)
Table 110. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Country (2018-2023)
Table 111. Middle East and Africa Hepatitis Drugs Sales by Country (2024-2029) & (K Units)
Table 112. Middle East and Africa Hepatitis Drugs Sales Market Share in Volume by Country (2024-2029)
Table 113. Middle East and Africa Hepatitis Drugs Sales by Country (2024-2029) & (US$ Million)
Table 114. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Country (2024-2029)
Table 115. F. Hoffmann-La Roche Company Information
Table 116. F. Hoffmann-La Roche Introduction and Business Overview
Table 117. F. Hoffmann-La Roche Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. F. Hoffmann-La Roche Hepatitis Drugs Product
Table 119. F. Hoffmann-La Roche Recent Development
Table 120. Gilead Sciences Company Information
Table 121. Gilead Sciences Introduction and Business Overview
Table 122. Gilead Sciences Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Gilead Sciences Hepatitis Drugs Product
Table 124. Gilead Sciences Recent Development
Table 125. GlaxoSmithKline Company Information
Table 126. GlaxoSmithKline Introduction and Business Overview
Table 127. GlaxoSmithKline Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. GlaxoSmithKline Hepatitis Drugs Product
Table 129. GlaxoSmithKline Recent Development
Table 130. Johnson & Johnson Company Information
Table 131. Johnson & Johnson Introduction and Business Overview
Table 132. Johnson & Johnson Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Johnson & Johnson Hepatitis Drugs Product
Table 134. Johnson & Johnson Recent Development
Table 135. Merck Company Information
Table 136. Merck Introduction and Business Overview
Table 137. Merck Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Merck Hepatitis Drugs Product
Table 139. Merck Recent Development
Table 140. Novartis Company Information
Table 141. Novartis Introduction and Business Overview
Table 142. Novartis Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Novartis Hepatitis Drugs Product
Table 144. Novartis Recent Development
Table 145. Vertex Pharmaceuticals Company Information
Table 146. Vertex Pharmaceuticals Introduction and Business Overview
Table 147. Vertex Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Vertex Pharmaceuticals Hepatitis Drugs Product
Table 149. Vertex Pharmaceuticals Recent Development
Table 150. Abbvie Company Information
Table 151. Abbvie Introduction and Business Overview
Table 152. Abbvie Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 153. Abbvie Hepatitis Drugs Product
Table 154. Abbvie Recent Development
Table 155. Achillion Pharmaceuticals Company Information
Table 156. Achillion Pharmaceuticals Introduction and Business Overview
Table 157. Achillion Pharmaceuticals Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 158. Achillion Pharmaceuticals Hepatitis Drugs Product
Table 159. Achillion Pharmaceuticals Recent Development
Table 160. Bristol-Myers Squibb Company Information
Table 161. Bristol-Myers Squibb Introduction and Business Overview
Table 162. Bristol-Myers Squibb Hepatitis Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2023)
Table 163. Bristol-Myers Squibb Hepatitis Drugs Product
Table 164. Bristol-Myers Squibb Recent Development
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Hepatitis Drugs Market Trends
Table 168. Hepatitis Drugs Market Drivers
Table 169. Hepatitis Drugs Market Challenges
Table 170. Hepatitis Drugs Market Restraints
Table 171. Hepatitis Drugs Distributors List
Table 172. Hepatitis Drugs Downstream Customers
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatitis Drugs Product Picture
Figure 2. Global Hepatitis Drugs Market Size, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Hepatitis Drugs Market Size Status and Outlook (2018-2029) & (US$ Million)
Figure 4. Global Hepatitis Drugs Sales Status and Outlook (2018-2029) & (K Units)
Figure 5. Product Picture of VEMLIDY
Figure 6. Global VEMLIDY Sales YoY Growth (2018-2029) & (K Units)
Figure 7. Product Picture of EPCLUSA
Figure 8. Global EPCLUSA Sales YoY Growth (2018-2029) & (K Units)
Figure 9. Product Picture of SOVALDI
Figure 10. Global SOVALDI Sales YoY Growth (2018-2029) & (K Units)
Figure 11. Product Picture of INCIVEK
Figure 12. Global INCIVEK Sales YoY Growth (2018-2029) & (K Units)
Figure 13. Product Picture of OLYSIO
Figure 14. Global OLYSIO Sales YoY Growth (2018-2029) & (K Units)
Figure 15. Product Picture of VICTRELIS
Figure 16. Global VICTRELIS Sales YoY Growth (2018-2029) & (K Units)
Figure 17. Product Picture of VIREAD
Figure 18. Global VIREAD Sales YoY Growth (2018-2029) & (K Units)
Figure 19. Product Picture of HEPSERA
Figure 20. Global HEPSERA Sales YoY Growth (2018-2029) & (K Units)
Figure 21. Product Picture of BARACLUDE
Figure 22. Global BARACLUDE Sales YoY Growth (2018-2029) & (K Units)
Figure 23. Product Picture of TYZEKA
Figure 24. Global TYZEKA Sales YoY Growth (2018-2029) & (K Units)
Figure 25. Global Hepatitis Drugs Sales by Type (2018-2029) & (US$ Million)
Figure 26. Global Hepatitis Drugs Sales Market Share by Type in 2022 & 2029
Figure 27. North America Hepatitis Drugs Sales Market Share in Volume by Type in 2022
Figure 28. North America Hepatitis Drugs Sales Market Share in Value by Type in 2022
Figure 29. Europe Hepatitis Drugs Sales Market Share in Volume by Type in 2022
Figure 30. Europe Hepatitis Drugs Sales Market Share in Value by Type in 2022
Figure 31. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Type in 2022
Figure 32. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Type in 2022
Figure 33. Latin America Hepatitis Drugs Sales Market Share in Volume by Type in 2022
Figure 34. Latin America Hepatitis Drugs Sales Market Share in Value by Type in 2022
Figure 35. Middle East and Africa Hepatitis Drugs Sales Market Share in Volume by Type in 2022
Figure 36. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Type in 2022
Figure 37. The 5 and 10 Largest Manufacturers in the World: Market Share by Hepatitis Drugs Sales in 2022
Figure 38. The 5 and 10 Largest Manufacturers in the World: Market Share by Hepatitis Drugs Revenue in 2022
Figure 39. Hepatitis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 40. Product Picture of Hepatitis A
Figure 41. Global Hepatitis A Sales YoY Growth (2018-2029) & (K Units)
Figure 42. Product Picture of Hepatitis B
Figure 43. Global Hepatitis B Sales YoY Growth (2018-2029) & (K Units)
Figure 44. Product Picture of Hepatitis C
Figure 45. Global Hepatitis C Sales YoY Growth (2018-2029) & (K Units)
Figure 46. Product Picture of Hepatitis D
Figure 47. Global Hepatitis D Sales YoY Growth (2018-2029) & (K Units)
Figure 48. Product Picture of Hepatitis E
Figure 49. Global Hepatitis E Sales YoY Growth (2018-2029) & (K Units)
Figure 50. Global Hepatitis Drugs Sales by Application (2018-2029) & (US$ Million)
Figure 51. Global Hepatitis Drugs Sales Market Share by Application in 2022 & 2029
Figure 52. North America Hepatitis Drugs Sales Market Share in Volume by Application in 2022
Figure 53. North America Hepatitis Drugs Sales Market Share in Value by Application in 2022
Figure 54. Europe Hepatitis Drugs Sales Market Share in Volume by Application in 2022
Figure 55. Europe Hepatitis Drugs Sales Market Share in Value by Application in 2022
Figure 56. Asia-Pacific Hepatitis Drugs Sales Market Share in Volume by Application in 2022
Figure 57. Asia-Pacific Hepatitis Drugs Sales Market Share in Value by Application in 2022
Figure 58. Latin America Hepatitis Drugs Sales Market Share in Volume by Application in 2022
Figure 59. Latin America Hepatitis Drugs Sales Market Share in Value by Application in 2022
Figure 60. Middle East and Africa Hepatitis Drugs Sales Market Share in Value by Application in 2022
Figure 61. Key Raw Materials Price
Figure 62. Hepatitis Drugs Manufacturing Cost Structure
Figure 63. Hepatitis Drugs Industrial Chain Analysis
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed 
